Real‑World Efficacy Evidence From Europe
This image is for illustrative purposes only.
Real‑World Efficacy Evidence From Europe
Real-world effectiveness study in Europe15
Following three months of treatment with ruxolitinib cream, patients with prior inadequate response to multiple topical and systemic therapies demonstrated clinically significant repigmentation.15
Median F-VASI reduced from 1.0 to 0.34 and T-VASI from 2.09 to 0.95 (p<0.001).15
F-VASI75 achieved in 40% and T-VASI50 in 42% of patients by Week 12.15
Improvements also seen in DLQI, and VitiQoL scores, reflecting enhanced quality of life.15
Median DLQI score reduced from 7 to 2 (p<0.001)15
Median VitiQoL score reduced from 54 to 25 (p<0.001)15
BID: twice a day; BSA: Body surface area; F-BSA: facial body surface area; F-VASI: Facial Vitiligo Area Scoring Index; T-BSA: total body surface area.
Reference
- Cristallo M, et al. Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non- Segmental Vitiligo: A Real- Life Study. Int J Dermatol 2025;0:1–3.
